Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease

De qué trata este estudio

El registro no identifica actualmente este estudio como reclutando. Consulta su estado antes de planificar una evaluación.

Tipo de estudio

De intervención

Fase

Fase 3

Rango de edad

6 años - 16 años

Sexo admitido

Todos los sexos

Voluntarios sanos

No aceptados

Participantes

45 Estimado

Estos son puntos de partida, no una decisión de elegibilidad. El equipo debe revisar todos los requisitos.

Acerca de la investigación

This study will be conducted to assess the safety and tolerability of ferric citrate in pediatric participants with hyperphosphatemia related to chronic kidney disease (CKD).

¿Quién podría participar?

La lista siguiente contiene el texto del patrocinador. Puede incluir condiciones, tratamientos previos, resultados de pruebas y otros requisitos. Aparecer en tu búsqueda no significa que califiques.

Inclusion Criteria:

• Age 6 years to \<17 years at Screening.
• Weight ≥ 20 kilograms (kg) (dry weight for dialysis participants) at Screening.
• Chronic kidney disease (CKD) requiring chronic dialysis (i.e., hemodialysis or peritoneal dialysis), or CKD not on dialysis with an estimated glomerular filtration rate (eGFR) \<30 milliliters per minute (mL/min)/1.73 meters squared (m\^2) at Screening.
• Documented history of CKD-related hyperphosphatemia for at least 3 months prior to the screening visit.
• If participant is or is not on phosphate binder(s) at Visit 1, serum phosphorus must be:

• 6 to \<13 years: \>5.8 milligrams per deciliter (mg/dL).
• 13 to \<17 years: \>4.5 mg/dL.
• If participant is on phosphate binder(s) at Visit 1, and serum phosphorus is not greater than the above stated age-limit criteria, approximately 1 to 4-weeks of washout period is required and at Visit 1a or Visit 1b, serum phosphorus must be greater than the age above stated age-limit criteria.
• Transferrin saturation (TSAT) \<50%.
• Serum ferritin of \<650 nanograms per milliliter (ng/mL).
• Parent/legal guardian must be willing and able to give written informed consent, and child (participant) willing and able to give age-appropriate assent according to local regulatory requirements.
• Female participants of childbearing potential, defined as post menarche and not surgically sterile, must have a negative serum pregnancy test.
• Dialysis adequacy stable on current mode of dialysis prior to screening and agree to maintain dialysis prescription for the duration of the pharmacodynamic assessment period unless changes are needed for safety. A minimum dialysis adequacy (dialysis clearance of urea-dialysis time/volume of distribution of urea \[Kt/V\]), defined by the following:

1. Hemodialysis adequacy: single-pool Kt/V ≥1.2 for at least 1 hemodialysis session within 2 months.
2. Peritoneal dialysis: At least 1Kt/V reading ≥1.8 within 4 months.

Exclusion Criteria:

• Active significant GI disorder, including overt GI bleeding or active inflammatory bowel disease.
• Liver transaminases (aspartate aminotransferase \[AST\] or alanine aminotransferase \[ALT\]) \>3× the upper limit of normal at Screening.
• Unable to swallow pills, if participant requires tube feeding, ferric citrate must be taken orally and not administered via feeding tube.
• Non-renal cause of hyperphosphatemia.
• Active drug or alcohol dependence or abuse (excluding tobacco use or medicinal marijuana) within the 12 months prior to Screening or evidence of such abuse (in the opinion of the Investigator).
• Malignancy, except for participants who have been disease-free for at least 2 years after curative therapy.
• Participants with a functioning organ transplant.
• A known allergy or intolerance to ferric citrate or any of its constituents.
• Female participants who do not agree to remain abstinent or assent to use a combination of 2 of the following highly effective birth control methods for at least 28 days before the first dose, during the study (including during dose interruptions), and for at least 30 days after the last dose:

• Barrier method of contraception: condoms (female or male) with or without a spermicidal agent, diaphragm, or cervical cap with spermicide.
• Intrauterine device (IUD).
• Hormone-based contraceptives which are associated with inhibition of ovulation.
• Females who are pregnant or breast-feeding other children. Participants who are being breastfed are eligible to participate in this study.
• Any other medical condition that, in the opinion of the Investigator, renders the participant unable to or unlikely to complete the trial or that would interfere with optimal participation in the trial or produce significant risk to the participant.
• The participant, in the opinion of the Investigator, is unable to adhere to the requirements of the study.
• Receipt of any investigational drug within 4 weeks before Screening.
• History of hemochromatosis or iron overload syndrome (e.g, hereditary sideroblastic anemia, thalassemia).

Tratamiento, grupos y participación

El registro puede describir tratamientos y duración sin incluir un calendario completo. Pide al equipo las visitas, procedimientos, riesgos, costos y alternativas. Mantén tu atención habitual salvo que tu médico te indique un cambio.

Asignación

No aplica

Enmascaramiento

Sin enmascaramiento

Qué evalúan los investigadores

Estas medidas indican qué se estudia. No prueban que un tratamiento funcione.

Medidas principales

Medidas secundarias

Centros de investigación (14)

El estado general puede diferir del estado de un centro. Confirma la disponibilidad antes de trasladarte.

14 centros

Equipo y fechas

Patrocinador principal

Keryx Biopharmaceuticals

Inicio del estudio

16 jun 2022 Real

Finalización primaria

2027-02 Estimado

Finalización del estudio

2027-10 Estimado

Primera publicación

24 ago 2020 Real

Última actualización

10 nov 2026 Real

Contactos oficiales del estudio

No hay un contacto central indicado. Revisa los centros y el registro oficial.